Humana Inc. Q2 FY26 Earnings Analysis

- Membership growth trajectory is on track, with dynamic management of distribution and growth if needed (Page 2). - Solid growth across CenterWell's lines of business: pharmacy, primary care (including recent Max Health acquisition), and home health (Page 6). - Expansion of CenterWell’s reach into new critical markets through acquisitions like Max Health (Page 2, 6). - Continued Medicaid membership growth (~50,000 lives) from new program starts in Michigan, Illinois, and South Carolina (Page 2). - Anticipated doubling of individual Medicare Advantage (MA) margin in 2026, reflecting improved operational performance and pricing discipline (Page 2). - Stable and compelling MA margin expected, unlocking earnings potential by 2028 (Page 3). - Growth expected from diversified business lines beyond benefits, supported by mature transformation efforts (Page 12). - Emphasis on retention and quality improvements to support sustainable long-term growth (Page 5).

- Humana expects to double individual Medicare Advantage (MA) margins in 2026, adjusted for Stars performance. - Focus is on returning to a sustainable margin of at least 3% by 2028, with progress to be made in 2027. - Pricing discipline and tight cost management, including operating cost reductions and tactical/strategic measures, support margin improvement. - Operating leverage continues to be a meaningful contributor to earnings growth through 2028. - Membership growth trajectory remains on track, which supports stable and compelling MA margins. - Capital allocation includes strategic acquisitions (e.g., Max Health) and noncore asset divestitures to fund growth. - Guidance for 2026 PDP (Prescription Drug Plan) business remains in line with expectations, supporting overall earnings stability. - Management remains cautious but confident in navigating bids and benefit adjustments to meet long-term earnings targets.

- Humana is pursuing noncore asset divestitures to help fund strategic acquisitions and expects to share more news on this in the coming months. (Page 3) - They have executed initiatives to optimize the balance sheet, including subsidiary reinsurance and legal entity restructuring, mitigating over $3 billion in capital contribution requirements for 2026. (Page 3) - Issued $1 billion junior subordinated notes in March, expected to fund 2027 maturities, indicating capital management and funding for future investments. (Page 3) - Continuing to evaluate a pipeline of initiatives to further strengthen the balance sheet, supporting ongoing and future strategic investments. (Page 3)

- Humana is maintaining dividend levels and limiting share repurchases to offset employee stock compensation dilution. - They intend to increase dividends and share repurchases when cash flows and funding capacity grow with the execution of their plan. - The company is pursuing noncore asset divestitures to help fund strategic acquisitions, with more updates expected in the coming months. - Recent initiatives include issuing $1 billion junior subordinated notes in March to fund 2027 maturities. - Additional efforts to optimize the balance sheet involve subsidiary reinsurance and augmenting legal entity structures, mitigating over $3 billion in capital contribution requirements for 2026. - Any potential cash obligations related to partner Welsh Carson's put options (around $1 billion to $1.5 billion in 2027) are included in Humana's funding plan. - Overall, Humana is actively managing debt and equity strategies but no immediate equity issuance is mentioned explicitly.

The provided document does not include specific information regarding the company's current or expected orderbook or pending orders. The discussion primarily focuses on: - Operational progress and transformation office roles - Medicare Advantage (MA) membership growth and performance - Margin and bid strategy outlook for 2027 and 2028 - Cost management and operating leverage initiatives - Claims monitoring, funding environment, and benefit adjustments - Capital deployment and balance sheet enhancements No explicit reference or data on orderbook, pending orders, or backlog is mentioned in the material on pages 5, 8, 9, 10, and 12.